These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38753770)

  • 61. Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.
    Jones DI; Pollara JJ; Johnson-Weaver BT; LaBranche CC; Montefiori DC; Pickup DJ; Permar SR; Abraham SN; Maddaloni M; Pascual DW; Staats HF
    J Virol; 2019 Jul; 93(14):. PubMed ID: 31068425
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.
    McGuire AT; Gray MD; Dosenovic P; Gitlin AD; Freund NT; Petersen J; Correnti C; Johnsen W; Kegel R; Stuart AB; Glenn J; Seaman MS; Schief WR; Strong RK; Nussenzweig MC; Stamatatos L
    Nat Commun; 2016 Feb; 7():10618. PubMed ID: 26907590
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development?
    Medina-Ramírez M; Sanders RW; Klasse PJ
    Expert Rev Vaccines; 2014 Apr; 13(4):449-52. PubMed ID: 24606603
    [TBL] [Abstract][Full Text] [Related]  

  • 64. All eyes on the next generation of HIV vaccines: strategies for inducing a broadly neutralizing antibody response.
    Ahlers JD
    Discov Med; 2014 Apr; 17(94):187-99. PubMed ID: 24759623
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants.
    Martinez DR; Tu JJ; Kumar A; Mangold JF; Mangan RJ; Goswami R; Giorgi EE; Chen J; Mengual M; Douglas AO; Heimsath H; Saunders KO; Nicely NI; Eudailey J; Hernandez G; Morgan-Asiedu PK; Wiehe K; Haynes BF; Moody MA; LaBranche C; Montefiori DC; Gao F; Permar SR
    mBio; 2020 Mar; 11(2):. PubMed ID: 32156815
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env.
    Escolano A; Gristick HB; Gautam R; DeLaitsch AT; Abernathy ME; Yang Z; Wang H; Hoffmann MAG; Nishimura Y; Wang Z; Koranda N; Kakutani LM; Gao H; Gnanapragasam PNP; Raina H; Gazumyan A; Cipolla M; Oliveira TY; Ramos V; Irvine DJ; Silva M; West AP; Keeffe JR; Barnes CO; Seaman MS; Nussenzweig MC; Martin MA; Bjorkman PJ
    Sci Transl Med; 2021 Nov; 13(621):eabk1533. PubMed ID: 34818054
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CD4+ T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques.
    Sarkar S; Spencer DA; Barnette P; Pandey S; Sutton WF; Basu M; Burch RE; Cleveland JD; Rosenberg AF; Rangel-Moreno J; Keefer MC; Hessell AJ; Haigwood NL; Kobie JJ
    Front Immunol; 2021; 12():757811. PubMed ID: 34745131
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001.
    Costa MR; Pollara J; Edwards RW; Seaman MS; Gorny MK; Montefiori DC; Liao HX; Ferrari G; Lu S; Wang S
    J Virol; 2016 Nov; 90(22):10362-10378. PubMed ID: 27630232
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers.
    Nyanhete TE; Edwards RJ; LaBranche CC; Mansouri K; Eaton A; Dennison SM; Saunders KO; Goodman D; Janowska K; Spreng RL; Zhang L; Mudrak SV; Hope TJ; Hora B; Bradley T; Georgiev IS; Montefiori DC; Acharya P; Tomaras GD
    Front Immunol; 2021; 12():670561. PubMed ID: 35003053
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Vaccination induces HIV broadly neutralizing antibody precursors in humans.
    Leggat DJ; Cohen KW; Willis JR; Fulp WJ; deCamp AC; Kalyuzhniy O; Cottrell CA; Menis S; Finak G; Ballweber-Fleming L; Srikanth A; Plyler JR; Schiffner T; Liguori A; Rahaman F; Lombardo A; Philiponis V; Whaley RE; Seese A; Brand J; Ruppel AM; Hoyland W; Yates NL; Williams LD; Greene K; Gao H; Mahoney CR; Corcoran MM; Cagigi A; Taylor A; Brown DM; Ambrozak DR; Sincomb T; Hu X; Tingle R; Georgeson E; Eskandarzadeh S; Alavi N; Lu D; Mullen TM; Kubitz M; Groschel B; Maenza J; Kolokythas O; Khati N; Bethony J; Crotty S; Roederer M; Karlsson Hedestam GB; Tomaras GD; Montefiori D; Diemert D; Koup RA; Laufer DS; McElrath MJ; McDermott AB; Schief WR
    Science; 2022 Dec; 378(6623):eadd6502. PubMed ID: 36454825
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.
    Kumar R; Tuen M; Li H; Tse DB; Hioe CE
    Vaccine; 2011 Nov; 29(48):9064-74. PubMed ID: 21945958
    [TBL] [Abstract][Full Text] [Related]  

  • 72. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
    LaBranche CC; McGuire AT; Gray MD; Behrens S; Kwong PDK; Chen X; Zhou T; Sattentau QJ; Peacock J; Eaton A; Greene K; Gao H; Tang H; Perez LG; Chen X; Saunders KO; Kwong PD; Mascola JR; Haynes BF; Stamatatos L; Montefiori DC
    PLoS Pathog; 2018 Nov; 14(11):e1007431. PubMed ID: 30395637
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.
    Voss JE; Andrabi R; McCoy LE; de Val N; Fuller RP; Messmer T; Su CY; Sok D; Khan SN; Garces F; Pritchard LK; Wyatt RT; Ward AB; Crispin M; Wilson IA; Burton DR
    Cell Rep; 2017 Oct; 21(1):222-235. PubMed ID: 28978475
    [TBL] [Abstract][Full Text] [Related]  

  • 74. mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice.
    Mu Z; Wiehe K; Saunders KO; Henderson R; Cain DW; Parks R; Martik D; Mansouri K; Edwards RJ; Newman A; Lu X; Xia SM; Eaton A; Bonsignori M; Montefiori D; Han Q; Venkatayogi S; Evangelous T; Wang Y; Rountree W; Korber B; Wagh K; Tam Y; Barbosa C; Alam SM; Williams WB; Tian M; Alt FW; Pardi N; Weissman D; Haynes BF
    Cell Rep; 2022 Mar; 38(11):110514. PubMed ID: 35294883
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Innovative approaches to track lymph node germinal center responses to evaluate development of broadly neutralizing antibodies in human HIV vaccine trials.
    Patricia D'Souza M; Allen MA; Baumblatt JAG; Boggiano C; Crotty S; Grady C; Havenar-Daughton C; Heit A; Hu DJ; Kunwar N; McElrath MJ;
    Vaccine; 2018 Sep; 36(38):5671-5677. PubMed ID: 30097219
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cross-Reactivity to Kynureninase Tolerizes B Cells That Express the HIV-1 Broadly Neutralizing Antibody 2F5.
    Finney J; Yang G; Kuraoka M; Song S; Nojima T; Verkoczy L; Kitamura D; Haynes BF; Kelsoe G
    J Immunol; 2019 Dec; 203(12):3268-3281. PubMed ID: 31732530
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.
    Walker LM; Simek MD; Priddy F; Gach JS; Wagner D; Zwick MB; Phogat SK; Poignard P; Burton DR
    PLoS Pathog; 2010 Aug; 6(8):e1001028. PubMed ID: 20700449
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting.
    Cheng C; Xu K; Kong R; Chuang GY; Corrigan AR; Geng H; Hill KR; Jafari AJ; O'Dell S; Ou L; Rawi R; Rowshan AP; Sarfo EK; Sastry M; Saunders KO; Schmidt SD; Wang S; Wu W; Zhang B; Doria-Rose NA; Haynes BF; Scorpio DG; Shapiro L; Mascola JR; Kwong PD
    PLoS One; 2019; 14(4):e0215163. PubMed ID: 30995238
    [TBL] [Abstract][Full Text] [Related]  

  • 79. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen.
    Jardine JG; Kulp DW; Havenar-Daughton C; Sarkar A; Briney B; Sok D; Sesterhenn F; Ereño-Orbea J; Kalyuzhniy O; Deresa I; Hu X; Spencer S; Jones M; Georgeson E; Adachi Y; Kubitz M; deCamp AC; Julien JP; Wilson IA; Burton DR; Crotty S; Schief WR
    Science; 2016 Mar; 351(6280):1458-63. PubMed ID: 27013733
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.
    Hoot S; McGuire AT; Cohen KW; Strong RK; Hangartner L; Klein F; Diskin R; Scheid JF; Sather DN; Burton DR; Stamatatos L
    PLoS Pathog; 2013 Jan; 9(1):e1003106. PubMed ID: 23300456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.